Research programme: psilocin derivatives - Enveric Biosciences
Latest Information Update: 07 Jun 2023
At a glance
- Originator Enveric Biosciences
- Class Neuropsychotherapeutics; Small molecules; Tryptamines
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Mental disorders
Most Recent Events
- 22 May 2023 Preclinical trials in Mental disorders in Italy (unspecified route) before May 2023
- 22 May 2023 Pharmacokinetics and pharmacodynamics data from preclinical studies in Mental disorders released by Enveric Biosciences
- 01 Mar 2022 Research programme: psilocin derivatives is available for licensing as of 01 Mar 2022. https://www.enveric.com/contact/